Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK536687PMID: 30694619
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1803171-55-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of ravulizumab during breastfeeding. Because ravulizumab is a large protein molecule with a molecular weight of about 148,000 Da, absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] The manufacturer recommends that breastfeeding be discontinued during ravulizumab therapy and for 8 months after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
Substance Identification
Substance Name
Ravulizumab
CAS Registry Number
1803171-55-2
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Galcanezumab.[Drugs and Lactation Database (...]Review Galcanezumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Vilobelimab.[Drugs and Lactation Database (...]Review Vilobelimab.. Drugs and Lactation Database (LactMed®). 2006
- Review Pembrolizumab.[Drugs and Lactation Database (...]Review Pembrolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Tildrakizumab.[Drugs and Lactation Database (...]Review Tildrakizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Benralizumab.[Drugs and Lactation Database (...]Review Benralizumab.. Drugs and Lactation Database (LactMed®). 2006
- Ravulizumab - Drugs and Lactation Database (LactMed®)Ravulizumab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...